Bristol-Myers Squibb Co - ESG Rating & Company Profile powered by AI
This ESG score includes seventeen United Nations Sustainable Development Goals including: 'Clean Water & Sanitation', 'Industry, Innovation & Infrastructure' and 'Peace, Justice & Strong Institutions'. The webpage contains a zero-cost Sustainability analysis for Bristol-Myers Squibb Co. This ESG score for Bristol-Myers Squibb Co represents the company's transparency towards the UN SDGs.
Bristol-Myers Squibb Co in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 8.0; made up of an environmental score of 8.0, social score of 8.0 and governance score of 8.0.
8.0
High ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Bristol-Myers Squibb Co | 8.0 | High |
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Bristol-Myers Squibb Co have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Bristol-Myers Squibb Co disclose current and historical energy intensity?
Sign up for free to unlockDoes Bristol-Myers Squibb Co report the average age of the workforce?
Sign up for free to unlockDoes Bristol-Myers Squibb Co reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Bristol-Myers Squibb Co disclose its ethnicity pay gap?
Sign up for free to unlockDoes Bristol-Myers Squibb Co disclose cybersecurity risks?
Sign up for free to unlockDoes Bristol-Myers Squibb Co use carbon offsets or credits exclusively for residual emissions (typically less than ~0.5–5% of total emissions)?
Sign up for free to unlockDoes Bristol-Myers Squibb Co offer flexible work?
Sign up for free to unlockDoes Bristol-Myers Squibb Co have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Bristol-Myers Squibb Co disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Bristol-Myers Squibb Co plan to change its portfolio composition to lower the emissions intensity of its energy mix (e.g., by shifting from oil to gas, or by adding lower-carbon options like hydrogen, e-fuels, bioenergy, etc.)?
Sign up for free to unlockDoes Bristol-Myers Squibb Co conduct supply chain audits?
Sign up for free to unlockDoes Bristol-Myers Squibb Co disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Bristol-Myers Squibb Co conduct 360 degree staff reviews?
Sign up for free to unlockDoes Bristol-Myers Squibb Co disclose the individual responsible for D&I?
Sign up for free to unlockDoes Bristol-Myers Squibb Co disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Bristol-Myers Squibb Co disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Bristol-Myers Squibb Co disclose water use targets?
Sign up for free to unlockDoes Bristol-Myers Squibb Co have careers partnerships with academic institutions?
Sign up for free to unlockDid Bristol-Myers Squibb Co have a product recall in the last two years?
Sign up for free to unlockDoes Bristol-Myers Squibb Co disclose incidents of discrimination?
Sign up for free to unlockDoes Bristol-Myers Squibb Co allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Bristol-Myers Squibb Co issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Bristol-Myers Squibb Co disclose parental leave metrics?
Sign up for free to unlockDoes Bristol-Myers Squibb Co disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Bristol-Myers Squibb Co disclose current and / or historical scope 1 emissions?
Sign up for free to unlockDoes Bristol-Myers Squibb Co explicitly state that carbon offsets or credits are separate from its emissions-reduction progress or that they are not counted toward its emissions-reduction targets?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Bristol-Myers Squibb Co disclose the pay ratio of women to men?
Sign up for free to unlockDoes Bristol-Myers Squibb Co support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Bristol-Myers Squibb Co disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Bristol-Myers Squibb Co reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Bristol-Myers Squibb Co involved in embryonic stem cell research?
Sign up for free to unlockDoes Bristol-Myers Squibb Co disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Bristol-Myers Squibb Co disclose its waste policy?
Sign up for free to unlockDoes Bristol-Myers Squibb Co report according to TCFD requirements?
Sign up for free to unlockDoes Bristol-Myers Squibb Co plan to mitigate emissions from future new production assets through measures such as electrifying equipment, carbon capture and storage, repurposing waste gas, methane leak detection and repair, eliminating flaring, etc.?
Sign up for free to unlockDoes Bristol-Myers Squibb Co disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Bristol-Myers Squibb Co disclose energy use targets?
Sign up for free to unlockDoes Bristol-Myers Squibb Co disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Bristol-Myers Squibb Co have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Bristol-Myers Squibb Co
These potential risks are based on the size, segment and geographies of the company.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.